Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 465

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 465
---
                                                             
 ​                                                             
 ​                                                             
 Balance, December 31, 2024                                    
 Other comprehensive income before reclassifications           
 Amount reclassified from accumulated other comprehensive loss 
 Net current period other comprehensive income                 
 Balance, March 31, 2025                                       
 ​                                                             | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​                   
 Total Accumulated   
 Other Comprehensive 
 Loss                
 ​                   |    ​ 
    — 
    — 
    — 
    — 
    — 
    ​ |
|:--------------------------------------------------------------|:--|:--------------------|-----:|
| Balance, December 31, 2023                                    | ​ | $                   | -260 |
| Other comprehensive income before reclassifications           | ​ |                     |   69 |
| Amount reclassified from accumulated other comprehensive loss | ​ |                     |    — |
| Net current period other comprehensive income                 | ​ |                     |   69 |
| Balance, March 31, 2024                                       | ​ | $                   | -191 |

Amounts reclassified out of accumulated other comprehensive loss into net loss are determined by specific identification. There were reclassifications out of accumulated other comprehensive loss and into net loss for each of the three months ended March 31, 2025 and 2024.

4. Fair Value Measurements As of March 31, 2025and December 31, 2024, Cara’s financial instruments consisted of cash and cash equivalents, accounts receivable, net – related party, other receivables, prepaid expenses, accounts payable and accrued liabilities, and liability related to the sales of future royalties and milestones. The fair values of cash and cash equivalents, accounts receivable, net – related party, other receivables, prepaid expenses, accounts payable and accrued liabilities approximate their carrying values due to the short-term nature of these financial instruments. The fair value of the liability related to the sales of future royalties and milestones also approximates the carrying value.

F- 113

TVARDI THERAPEUTICS, INC. (Formerly Cara Therapeutics, Inc.) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (amounts in thousands, except share and per share data) (unaudited)

The following tables summarize Cara’s financial assets measured at fair value on a recurring basis as of March 31, 2025and December 31, 2024.

Fair value measurement as ofMarch 31, 2025:

Financial assets